Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?
Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?
复制标题
DOI：
10.1093/humrep/deg406
复制
发表时间：
2003-10-01
影响因子：
6.1
通讯作者：
Schmidt-Gollwitzer, K
中科院分区：
文献类型：
--
作者：
Machens, K;Schmidt-Gollwitzer, K
2002年7月，《美国医学协会杂志》发表了妇女健康倡议（WHI）过早停止雌激素加黄体酮研究的数据。心脏和雌激素/黄体酮替代研究（HERS/HERS II）的结果发表在同一期杂志上。健康绝经后妇女的WHI结果通常被解释为与已确诊冠心病的绝经后妇女的HERS/HERS II结果相似。由于HERS/HERS II和WHI，激素替代疗法的使用普遍受到质疑。总的来说，这是对激素替代疗法的不公正判断。对这两项研究的概括性回顾和批评将显示方法学上的弱点及其后果，以及WHI和HERS/HERS II对正常激素替代疗法使用者的研究结果具有有限普遍性的原因。
In July 2002 the data of the prematurely stopped Estrogen plus Progestin study of the Women's Health Initiative (WHI) were presented in the Journal of the American Medical Association. The results of the Heart and Estrogen/Progestin Replacement Study (HERS/HERS II) were published in the same issue. The results of WHI for healthy postmenopausal women often are interpreted to be in analogy with the HERS/HERS II results for postmenopausal women with established coronary heart disease. As a result of HERS/HERS II and WHI, use of HRT in general became questionable. This is an unjustified judgement of HRT in general. This synoptic review and criticism of both studies will show the methodological weaknesses and their consequences and the reasons for limited generalizability of the study results from WHI and HERS/HERS II on normal HRT users.